Clinical trial
A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy…
NCT00057525 · DynPort Vaccine Company LLC, A GDIT Company, Industry · Completed
Key facts
| NCT number | NCT00057525 |
|---|---|
| Title | A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults |
| Official title | A Phase 1 Study of Safety and Immunogenicity of E. Coli-Derived Recombinant Protective Antigen (rPA), a New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults |
| Lead sponsor | DynPort Vaccine Company LLC, A GDIT Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Anthrax |
| Intervention type | Biological |
| Interventions | Anthrax, Alhdryogel or PBS |
| Enrollment | 70 |
| Start date | Apr 1, 2003 |
| Primary completion | Apr 1, 2004 |
| Completion | Aug 1, 2004 |
| First posted | Apr 7, 2003 |
| Last update posted | Jun 30, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: